Physician profile
Charles Barsam
NPI 1760470041
$3,407.08
in general payments reported to CMS, 2019-2025
22 companies · $895 in 2025
The $895 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $192 · 2020: $90.57 · 2021: $377 · 2022: $347 · 2023: $714 · 2024: $792 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,401.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,430.69 | 2022-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $404.23 | 2021-2025 | Cequa |
| Alcon Vision LLC | $303.69 | 2019-2024 | Hydrus Microstent, Clareon |
| Biotissue Holdings INC. | $267.88 | 2021-2025 | |
| Allergan, INC. | $156.52 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $151.24 | 2022-2025 | Syfovre |
| Dompe US, INC. | $123.12 | 2020-2022 | |
| Glaukos Corporation | $104.47 | 2024-2025 | Idosetr, Ce-Marked Kxla System, Photrexa Viscous and Photrexa |
| Astellas Pharma US INC | $81.36 | 2024-2025 | Izervay |
| Regeneron Healthcare Solutions, INC. | $65.62 | 2021-2025 | Eylea Hd |
| Mallinckrodt Enterprises LLC | $58.38 | 2019 | |
| Bausch & Lomb Americas INC. | $35.17 | 2024 | Miebo, Xiidra |
| Eyevance Pharmaceuticals LLC | $34.83 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $33.24 | 2025 | Xeomin |
| Rxsight INC | $24.85 | 2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $23.73 | 2019 | |
| Sight Sciences, INC. | $21.87 | 2021 | |
| Shire North American Group INC | $19.95 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $19.27 | 2025 | Xdemvy |
| Kala Pharmaceuticals, INC. | $17.13 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $15.44 | 2024 | Lipiflow System Activator II (Disposable |
| Thea Pharma INC. | $14.40 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Barsam listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.